- Danish stocks
- First North Copenhagen
- Bavarian Nordic
- Chr. Hansen
- DanDrit Biotech
- GN Store Nord
- Novo Nordisk
- Veloxis Pharmaceuticals
- William Demant
- Zealand Pharma
- Norwegian stocks
- Swedish stocks
- A1M Pharma
- Accelerator Nordic
- Clinical Laserthermia
- Eurocine Vaccines
- European Inst. of Science
- IDL Biotech
- Medfield Diagnostics
- Micropos Medical
- Rubicon Life Science
- SPAGO Imaging
- Vivoline Medical
- First North Stockholm
- OMX Stockholm A-F
- OMX Stockholm G-Z
- US stocks
- General discussion
- All posts
Today BioPorto announced that they have entered into a Distribution Agreement with Wiener Group for an NGAL assay. The Agreement includes sale, marketing and registration process in Latin America
Wiener Group is Argentine based, working primarily in Argentina and Brazil (and other latin american countries) – info about the company can be found below.. The Wiener Group is – like Instrumentation Lab – a producer of analyzers. However – contrary to IL, Wiener Group has decided to use a homogenous Test on their analyzers (rather than develop their own heterogenous) , and are amongst the first machine producers to adopt the turbidemetry testformat for the NGAL test. The Wiener group already market other Turbitests…
I expect to see more such Agreements with local/regional players who have their own line of analyzers. In fact – I think we will se a steadily rising numbers of such Agreements in the near to medium term future, basically beacuse other the small/medium-sized manufacturers are aware of the risk of being left out… BioPorto will not have the capacity to validate all types of analyzers – so in order to have a leading edge they (the manufacturers) will have to undertake this themselves.
Now I know many of you still frown at hospitals in Brazil, Latin America and in the other Bric-countries such as China and India. But – please bear in mind – that the economy and living standard of the middle class in these countries are rising steeply.
Why is that – well those of us who have been to Africa lately, have witnessed that the phone-net in Africa is working smoothly, very smoothly in contrast to the infrastructure. The Africans simply bypassed the old copperbased systems and when straigth to state-of-the-art technology. The same thing is happening right now with the hospital-sector in the Bric Countries. Not being bound by old routines – og old machinery – this sector will be technology-driven – far faster thanEurope/US – where the financial crisis is still very much menu of the day..
Actually – I predict that The NGAL test will be integrated in routine diagnostics in China, India, Brazil and other advancing countries far more rapidly than in Europe. Indeed – this might be exactly the kind of breakthrough that companies like BioPorto can thrive on.
However – and this is also of paramount importance – BioPorto needs to sign Agreements with the Global Players as well, only they can PUSH the new technology in the still principal markets, and only they can initialize the intense marketing that is still needed. This Agreement (with Wiener Group) is NOT the Agreement that BioPorto has promised in Q2 – but it is significant in as much as it outlines the future for the NGAL test
- The first (and so far only) NGAL license agreement. In march 2011, Bioporto signed the first non-exclusive license agreement...
- NGAL-test – a marker for anemia ? The NGAL- test has hiherto primarily been connected with measurement...
- Will they ever bring the NGAL test to the market? In November 2010, a productmanager from Beckman Coulter Diagnostics said:...
- 2014 – a threat for Bioporto, the NGAL-patent or the NGAL-test ?? Uncertainty about consequences of the recent decision by the European...
- Spekulant.dk on Ny dansk medico IPO
- Spekulant.dk on Spændende norsk selskab
- @IFTAdk on Zealand Pharma pr. 27. sep. 2013
- Medicoinvestor on Foreløbig og ikke-bindende rapport om ankesagen for BioPortos cutoff-patent i Europa
- Jørgen Lauridsen on Foreløbig og ikke-bindende rapport om ankesagen for BioPortos cutoff-patent i Europa